Allogene Therapeutics (ALLO) Set to Announce Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Allogene Therapeutics to announce earnings of ($0.1466) per share and revenue of $0.00 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. The business had revenue of $4.64 million for the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect Allogene Therapeutics to post ($0.58) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $1.11 on Tuesday. Allogene Therapeutics has a 1 year low of $1.04 and a 1 year high of $4.46. The stock has a fifty day moving average price of $1.60 and a two-hundred day moving average price of $1.97. The stock has a market capitalization of $385.22 million, a price-to-earnings ratio of -1.65 and a beta of 0.56.

Insider Buying and Selling at Allogene Therapeutics

In related news, CFO Geoffrey Parker sold 36,342 shares of Allogene Therapeutics stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $1.34, for a total transaction of $48,698.28. Following the completion of the transaction, the chief financial officer directly owned 1,045,877 shares of the company’s stock, valued at approximately $1,401,475.18. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Earl Douglas sold 29,697 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $2.12, for a total value of $62,957.64. Following the sale, the senior vice president owned 488,267 shares in the company, valued at approximately $1,035,126.04. The trade was a 5.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 13.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ALLO shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $6.00 price target on shares of Allogene Therapeutics in a research note on Monday, August 17th. Weiss Ratings upgraded shares of Allogene Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, October 21st. Finally, William Blair upgraded shares of Allogene Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.30.

About Allogene Therapeutics

Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.

The company’s investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.